Nuvation Bio (NUVB) Profit After Tax (2020 - 2026)

Nuvation Bio (NUVB) has reported Profit After Tax for 7 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 107.34% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at -$147.5 million (up 75.56% YoY), while the FY2025 annual figure was -$204.6 million, up 63.95% from the prior year.
• Profit After Tax climbed to $3.9 million in Q1 2026 per NUVB's latest filing, from -$36.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at $3.9 million in Q1 2026 and bottomed at -$462.5 million in Q2 2024.
• Historically, Profit After Tax has averaged -$55.3 million across 5 years, with a median of -$28.3 million in 2022.
• Annual changes were most pronounced in 2024 — Profit After Tax slumped 2140.76% — and 2026, when it surged 107.34%.
• Nuvation Bio's Profit After Tax stood at -$18.3 million in 2022, then jumped by 43.53% to -$10.3 million in 2023, then plunged by 375.87% to -$49.1 million in 2024, then grew by 25.4% to -$36.6 million in 2025, then soared by 110.68% to $3.9 million in 2026.
• Business Quant data shows NUVB's Profit After Tax at $3.9 million in Q1 2026, -$36.6 million in Q4 2025, and -$55.8 million in Q3 2025.